Fundz

FesariusTherapeutics secures $20M in an oversubscribed Series A round, led by Jefferson Life Sciences, to advance its innovative DermiSphere technology.

PRIVATEJun 10, 2026

Amount Raised

$20 Million

Round Type

Series A

New YorkManufacturingBiotechnologyHealth CareMedicalMedical Device

Investors

Johnson & JohnsonAmerican Society Of Plastic SurgeonsEmpire State Development’s Ny VenturesJefferson Life Sciences

Description

FesariusTherapeutics has successfully closed a $20 million Series A financing round. The round was led by Jefferson Life Sciences, alongside investors like Johnson & Johnson Innovation and NY Ventures. This funding will help accelerate the company's commercial infrastructure and support clinical trials for its flagship product, DermiSphere™. The investment marks a significant milestone for Fesarius as it builds commercial momentum in U.S

Who to call at FesariusTherapeutics, and when

A new round usually means FesariusTherapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day FesariusTherapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at FesariusTherapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at FesariusTherapeutics. With Fundz connected, it knows.

See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

FesariusTherapeutics

Location

New York, New York, United States

About

FesariusTherapeutics is a commercial-stage medical technology company reimagining dermal repair. Its flagship product, DermiSphere™, is the first hydrogel Dermal Regeneration Template on the U.S. market, cleared by the FDA for managing various wound types. The company aims to transform wound care through innovative solutions that improve patient outcomes. With a focus on advancing its technologies, Fesarius is poised for significant growth in the medical device sector.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment FesariusTherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsTim O., Vice President of Sales & Marketing hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for FesariusTherapeutics's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

FesariusTherapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.